Across TCGA pan-cancer cohorts, C3orf84 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C3orf84 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher C3orf84 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C3orf84 expression acts as an unfavorable survival marker.
SKCM are the cancer types where C3orf84 Mutation most reproducibly stratifies survival.